|
Novian Health begins breast cancer trial
 April 12, 2012 -- Novian Health has begun a multicenter clinical trial on the use of its Novilase interstitial laser therapy (ILT) for the destruction of malignant breast tumors, the company said.
To view the remainder of this article, and other exclusive content, you must first sign-in or register using the options below.
(Helptag:PaywallArticleLoginMessage)
| |
|
|
New AuntMinnie.com Members
|
Becoming a Member is FREE!
|
Real-time radiology-specific news
Case of the Day and Teaching Files
Focused topics digital communities
Lively, discussion groups
Medical imaging bookstore
SalaryScan
Job Boards
OnLine CMe/CE
Bookstore, market reports, more …
Conference Calendar
User-controlled eNewsletters
… registration is FREE and easy!
|
| |
|
Novilase ILT is an image-guided, minimally invasive alternative for lumpectomy used to ablate small breast tumors. The new clinical trial is the first stage of a two-stage study as part of a U.S. Food and Drug Administration premarket approval (PMA) process, according to Novian Health.
Researchers will evaluate the rate of complete tumor ablation of breast cancers that are up to 2 cm, as well as the correlation of the pathology of postablation lumpectomy specimens with MRI, mammography, and ultrasound in detecting any residual tumor, the firm said. The first facility to participate in the trial is Rose Breast Center of Denver, CO. | |
|